查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1879277

缺鐵性貧血治療市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、最終用戶、地區和競爭格局分類，2020-2030年預測

Iron Deficiency Anemia Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球缺鐵性貧血治療市場規模為54.9億美元，預計2030年將以6.70%的複合年成長率成長至81億美元。缺鐵性貧血（IDA）治療主要包括藥物干預，例如口服和靜脈注射鐵劑，旨在補充體內耗竭的鐵儲備，從而促進足夠的血紅蛋白合成，並緩解缺鐵相關症狀。全球缺鐵性貧血盛行率的不斷上升、公眾和醫療界對早期診斷和有效治療的認知不斷提高，以及治療製劑的進步，是推動全球市場擴張的主要因素。

市場概覽
預測期 2026-2030
2024年市場規模 54.9億美元
2030年市場規模 81億美元
2025-2030年複合年成長率 6.7%
成長最快的細分市場 口服鐵劑治療
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球缺鐵性貧血治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療類型（口服鐵劑治療、腸外鐵劑治療、紅血球輸注）
    • 依最終使用者（醫院、診所、家庭醫療保健）分類
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美缺鐵性貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲缺鐵性貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區缺鐵性貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲缺鐵性貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲缺鐵性貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球缺鐵性貧血治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Daiichi Sankyo Company
  • Novartis AG
  • Rockwell Medical Inc
  • Iron4u Aps
  • AbbVie Inc
  • Sanofi
  • Disc Medicine Inc
  • Pfizer Inc
  • Akebia Therapeutics
  • Keros Therapeutics Inc

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16192

The Global Iron Deficiency Anemia Therapy Market, valued at USD 5.49 Billion in 2024, is projected to experience a CAGR of 6.70% to reach USD 8.10 Billion by 2030. Iron Deficiency Anemia (IDA) Therapy involves pharmaceutical interventions, primarily oral and intravenous iron supplements, designed to replenish depleted iron stores, thereby enabling adequate hemoglobin synthesis and alleviating symptoms associated with iron deficiency. The global market's expansion is significantly propelled by the increasing worldwide prevalence of iron deficiency anemia, heightened public and medical awareness concerning early diagnosis and effective management, and advancements in therapeutic formulations.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.49 Billion
Market Size 2030USD 8.10 Billion
CAGR 2025-20306.7%
Fastest Growing SegmentOral Iron Therapy
Largest MarketNorth America

Key Market Drivers

The rising prevalence of iron deficiency anemia fundamentally drives market expansion, creating a substantial global demand for effective therapeutic interventions. This widespread nutritional deficiency necessitates consistent, accessible treatment, directly propelling the growth of pharmaceutical and supplementary solutions. For instance, according to the World Health Organization, in February 2025, an estimated 269 million children aged 6-59 months worldwide were affected by anemia. This large patient demographic ensures continuous requirement for diagnosis and subsequent treatment, underpinning the market's sustained growth.

Key Market Challenges

The considerable cost associated with advanced intravenous iron therapies presents a significant challenging factor, directly impeding the growth of the Global Iron Deficiency Anemia Therapy Market. This high cost often results in restrictive reimbursement policies from payers, who may prioritize less expensive, older-generation intravenous iron formulations through mechanisms such as step therapy requirements. Such policies compel patients to first attempt therapies that may be less effective or require more frequent administrations.

Key Market Trends

The emergence of nanomedicine in iron formulations represents a significant advancement, addressing challenges associated with conventional iron therapies such as bioavailability and side effects. These novel formulations, designed at the nanoscale, offer improved absorption kinetics and reduced gastrointestinal distress, enhancing patient adherence and therapeutic outcomes. For instance, in February 2023, the IHAT-GUT trial published in *EClinicalMedicine* demonstrated that a novel nano-iron supplement, iron hydroxide adipate tartrate (IHAT), showed non-inferiority compared to standard ferrous sulfate for iron deficiency correction and hemoglobin response in children aged 6-35 months, warranting further Phase III trials.

Key Market Players

  • Daiichi Sankyo Company
  • Novartis AG
  • Rockwell Medical Inc
  • Iron4u Aps
  • AbbVie Inc
  • Sanofi
  • Disc Medicine Inc
  • Pfizer Inc
  • Akebia Therapeutics
  • Keros Therapeutics Inc

Report Scope:

In this report, the Global Iron Deficiency Anemia Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Therapy Market, By Therapy Type:

  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Red Blood Cell Transfusion

Iron Deficiency Anemia Therapy Market, By End User:

  • Hospitals
  • Clinics
  • Home Healthcare

Iron Deficiency Anemia Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Iron Deficiency Anemia Therapy Market.

Available Customizations:

Global Iron Deficiency Anemia Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Iron Deficiency Anemia Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion)
    • 5.2.2. By End User (Hospitals, Clinics, Home Healthcare)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Iron Deficiency Anemia Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Iron Deficiency Anemia Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Iron Deficiency Anemia Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Iron Deficiency Anemia Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By End User

7. Europe Iron Deficiency Anemia Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Iron Deficiency Anemia Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Iron Deficiency Anemia Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Iron Deficiency Anemia Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Iron Deficiency Anemia Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Iron Deficiency Anemia Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By End User

10. South America Iron Deficiency Anemia Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Iron Deficiency Anemia Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Iron Deficiency Anemia Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Iron Deficiency Anemia Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Iron Deficiency Anemia Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Daiichi Sankyo Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Rockwell Medical Inc
  • 15.4. Iron4u Aps
  • 15.5. AbbVie Inc
  • 15.6. Sanofi
  • 15.7. Disc Medicine Inc
  • 15.8. Pfizer Inc
  • 15.9. Akebia Therapeutics
  • 15.10. Keros Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer